Muthusamy Shanmugam
Board Member
Ani Pharmaceuticals Inc (ANIP)Personal wealth note: Equibles reports source-backed professional activity and disclosed compensation; it does not estimate personal net worth.
About Muthusamy Shanmugam
Muthusamy Shanmugam is recorded as COO and Board Member at Ani Pharmaceuticals Inc (ANIP). Ani Pharmaceuticals Inc reported in an 8-K filed August 24, 2026 that Muthusamy Shanmugam resigned as director, effective August 23, 2026. Ani Pharmaceuticals Inc reported in an 8-K filed May 21, 2026 that Muthusamy Shanmugam was appointed Director, effective May 21, 2026. Ani Pharmaceuticals Inc reported in an 8-K filed May 23, 2025 that Muthusamy Shanmugam was appointed director, effective May 22, 2025. Equibles holds 4 filed executive changes naming Muthusamy Shanmugam; each is listed under recent activity with its source filing.
“On August 23, 2026, Muthusamy "Samy" Shanmugam informed the Board of his decision to resign as a director effective immediately.”
“The election of seven (7) director nominees, each to serve until the Company’s 2027 Annual Meeting of Stockholders and thereafter until their successors are duly elected and qualified, or until their earlier death, resignation or removal”
Summary generated from SEC filings and earnings-call records held by Equibles.
Affiliation history
Recorded current and former roles; source labels appear when available.
-
Current
2026-05-21–present
-
Current
Start not stated–present
-
2026-05-21–2026-08-23
Company network
Recorded roles and call appearances connecting this person to public companies.
Leadership on record at Ani Pharmaceuticals Inc
Other people whose current roles at this company are on record from its filings.
- Nikhil Lalwani CEO, Board Member
- Patrick D. Walsh CEO, Board Member
- Thomas J. Haughey Chairman
- Stephen Carey CFO
- Meredith W. Cook General Counsel
- Antonio Pera Board Member
- Antonio R. Pera Board Member
- David B. Nash, M.D. Board Member
- Henry Gosebruch Board Member
- Jeanne A. Thoma Board Member
Recent activity
Earnings-call and investor-event appearances, plus filed executive appointments or departures, newest first.